Ovarian cancer is the eighth most common cancer worldwide in females and usually diagnosed at an advanced stage. Serum cancer antigen 125 (CA125) is widely used in ovarian cancer. An elevation in CA125 levels can precede a clinically apparent recurrence by 3 to 6 months and 18F-FDG PET/CT can modify management in approximately half of these patients. However. 18F-FDG PET/CT may yield false negative results. 68Ga-FAPI-46 PET/CT shows potential here. This study is to assess the diagnostic performances of 68Ga-FAPI-46 and 18F-FDG PET/CT for ovarian cancer recurrence in patients with CA125 elevation from complete response after therapy.
Age
30–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Pathologically proven ovarian cancer with complete response after therapy
Age between 30 and 80
Elevation of serum CA125 value above the normal range (\>35 U/mL) or doubling of serum CA125 value within the normal range
ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed
Willing to enter this prospective study with signed informed consent form
You may not be if
Patients with history of other malignancy
Patients who are pregnant or lactating
Patients with fasting fingerstick glucose level higher than 200 mg/dl
Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies
Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators
Clareo Health | Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer
